U.S. Medtech Market Growth: The Numbers Behind the Trends

The U.S. medtech market continues to be a dominant force globally, representing over 45% of the worldwide medtech revenue as of 2025. Despite recent concerns and headlines suggesting uncertainty, a deeper dive into the numbers tells a different story: one of resilience and steady expansion. Thanks to growing surgical procedure volumes and significant investments in innovation, the United States remains at the forefront of medtech development. In this article, we’ll explore the factors driving growth, key statistics, and the market’s long-term outlook for medtech companies.

U.S. Medtech Market Resilience Amidst Challenges

For the past several decades, the United States has remained the largest market for medical devices worldwide. Its dominance in the field is attributed to several factors: a robust ecosystem of research and development, a highly engaged healthcare workforce, and the adoption of cutting-edge technologies like surgical robotics and AI-powered diagnostics. As of 2025, U.S. medtech companies continue to lead the world in creating transformative healthcare innovations.

However, challenges such as trade policies, workforce shortages, and evolving regulatory landscapes have raised questions about the sustainability of this market. Despite these hurdles, the underlying growth trends and continued demand for innovative solutions signal a positive trajectory for U.S. medtech companies.

U.S. Medtech Market Growth by the Numbers

According to LSI’s recently updated Global Surgical Procedure Volumes (SPV) database, U.S. surgical procedure volumes increased by 3.7% from LSI’s 2024 dataset and the most recent release. This rise has resulted in an upward revision of the procedure volumes from an initial estimate of 92.3 million to 95.7 million in 2024. This growth rate has surpassed expectations, showing a 2.3% compound annual growth rate (CAGR) for 2024–2029, up from the previously projected 1.4%.

As we look forward to 2025, it is anticipated that the United States will perform approximately 97.8 million surgical procedures. The 100-million procedure milestone is on the horizon, likely to be surpassed by 2026 or 2027. This increase in volumes speaks to the growing demand for medical interventions, supported by an aging population and a healthcare system that continues to embrace new technologies.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/us-medtech-market-growth-the-numbers-behind-the-trends 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more